Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

7.7%

2 terminated out of 26 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

27%

7 trials in Phase 3/4

Results Transparency

50%

8 of 16 completed with results

Key Signals

8 with results89% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (11)
P 1 (1)
P 2 (5)
P 3 (2)
P 4 (5)

Trial Status

Completed16
Unknown4
Recruiting2
Terminated2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT06462391Not ApplicableActive Not RecruitingPrimary

Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms

NCT06496139Not ApplicableRecruitingPrimary

Emotion Regulation-based Internet-delivered Cognitive Behavioural Therapy for Premenstrual Dysphoric Disorder

NCT03862469Not ApplicableCompletedPrimary

Premenstrual Hormonal and Affective State Evaluation (PHASE) Project

NCT06648382Not ApplicableRecruiting

Pilot Study of the 'Thriving With PMDs' Program

NCT05098574Phase 2CompletedPrimary

Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder

NCT06136104Not ApplicableCompleted

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

NCT06227676Phase 2Completed

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NCT05813366Not ApplicableUnknownPrimary

Combined Effect of Tryptophan Rich Diet and Acupuncture on Depression Related to Premenstrual Dysphoric Disorder

NCT05327075UnknownPrimary

Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females

NCT01799733Not ApplicableCompletedPrimary

Alternative Treatments for Premenstrual Dysphoric Disorder

NCT03697265Phase 2CompletedPrimary

A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)

NCT02362191Not ApplicableTerminatedPrimary

Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD

NCT03449979Not ApplicableCompleted

Single Session of tACS in a Depressive Episode

NCT04123483Phase 4Withdrawn

EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders

NCT00678574Phase 4CompletedPrimary

The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

NCT00089414Phase 2Terminated

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

NCT02508103Phase 2CompletedPrimary

Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study

NCT00536198Phase 4CompletedPrimary

Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

NCT01385709Completed

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

NCT00927095Phase 4CompletedPrimary

Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

Scroll to load more

Research Network

Activity Timeline